Share
Jonathan Freeman
Cardiawave, a pioneering medtech company advancing Non-Invasive Ultrasound Therapy (NIUT) for aortic stenosis, has appointed Jonathan Freeman, PhD, as Chairman of its Board of Directors.
This strategic leadership enhancement marks a significant milestone in the company’s growth and underscores its commitment to redefining the treatment of aortic valve diseases worldwide.
Jonathan Freeman, an accomplished life sciences leader and serial entrepreneur, steps into this role at a transformative time for Cardiawave. The company recently concluded its Valvosoft® Pivotal study in Europe and is preparing to initiate its IDE trial in the United States, positioning itself for the next phase of clinical and commercial advancement.
Dr. Freeman brings an extensive international track record in building and scaling innovative therapeutic companies. He is the co-founder of Anthos Therapeutics, a cardiovascular-focused biopharmaceutical company acquired by Novartis in May 2025 for up to USD 3.1 billion. He also serves as a founding board member of Neurvati and GRIN Therapeutics and is an Operating Advisor at Blackstone Life Sciences. His earlier career includes senior leadership roles at globally recognized organizations such as Merck KGaA, Baxter International, Serono, and Vedanta Biosciences.
Holding a PhD in Molecular Pharmacology and an international MBA from Cambridge, Dr. Freeman brings both scientific depth and strategic business expertise to Cardiawave. His appointment bolsters the company’s governance and reinforces its mission to revolutionize non-invasive cardiovascular care on a global scale.
Related posts
-(2).jpg "Vicarious Surgical Appoints Joseph Doherty as Chairman of the Board")
